A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Calithera Biosciences, Inc.
Start Date
April 2, 2019
End Date
April 20, 2024
Administered By
Duke Cancer Institute
Awarded By
Calithera Biosciences, Inc.
Start Date
April 2, 2019
End Date
April 20, 2024